NEU chart, page-1867

This may be an unpopular opinion, but I'm not sure how our current valuation warrants a buyback. If anything, that is counter-intuitive to the fact that we have just gotten great phase 2 results. If our stance is still to look for best value by keeping our options of going alone open (or at least being seemingly happy to going alone if necessary) then I would assume that the best way of doing this would be to begin multiple phase 3 trials and release those other indications in the mean time.

We either have something, or we don't. I understand risk appetite and investment horizons will differ amongst shareholders, but I think this is a no-brainer from NEU's perspective. If no one comes along with a decent offer, just keep moving along.

Like many here, I'm still in NEU for NNZ2591. To date it has not disappointed, but rather confirmed what we thought we had. Though I would like the share price further north and a TO offer Yesterday, I also realize that valuations tend to be undervalued in almost all Australian Biotechs. It's almost a discount because we're not an American company. Nonetheless, I think our valuation of around $2b is still reasonable in my book given that the market tends to value biotechs at peanuts until Phase 3 results. E.g. IMU is valued around $500m, OPT $700m, CUV $700m.

If we consider NNZ2591 to be equivalent to IMU and OPT, $500-700m, that means Daybue valuation is around $1.3b-1.5billion. My comparisons are not perfect but I want to make the point that, Yes: current MC is cheap, but so are the MC of a number of other biotechs.

Anyhow, I have bought parcels too at our prices as I was hoping $14-$17 might prove to be the low. If not, I guess, might to buy some more...